文献速递细菌感染、耐药与抗菌药物

细菌拓扑异构酶抑制剂:喹诺酮类药物历史、临床应用与未来潜在替代方案

Bacterial DNA topoisomerase IV and DNA gyrase inhibitors: history of the quinolones, their clinical usage and potential alternatives for the future.
PubMed 文献 · J Antimicrob Chemother · 2026-01-01

细菌拓扑异构酶是维持基因组DNA完整性的关键酶,喹诺酮和氟喹诺酮通过抑制DNA旋转酶和拓扑异构酶IV发挥抗菌作用。氟喹诺酮类如左氧氟沙星和环丙沙星仍为重要治疗选择,但副作用引发警告且耐药率逐年上升。新型非喹诺酮类拓扑异构酶抑制剂(如zoliflodacin、gepotidacin和fobrepodacin)的临床开发为应对抗菌药物耐药提供了有希望的解决方案。

要点

  • 氟喹诺酮类仍为广谱有效抗菌药物,但需关注其副作用警告。
  • 氟喹诺酮耐药率在许多国家逐年上升,威胁公共健康。
  • 新型非喹诺酮拓扑异构酶抑制剂有望应对耐药问题。

核心结论

  • 氟喹诺酮类仍是重要治疗选择,但副作用和耐药上升带来挑战,新型非喹诺酮拓扑异构酶抑制剂具有潜力。

研究设计与样本

  • 综述文章,讨论喹诺酮和氟喹诺酮的发展、当前临床应用、未来挑战及新型拓扑异构酶抑制剂的潜力。

主要发现

  • 喹诺酮和氟喹诺酮靶向DNA旋转酶和拓扑异构酶IV,抑制DNA超螺旋/解链控制,导致DNA复制受损和细菌死亡。
  • 许多喹诺酮和氟喹诺酮对广泛细菌种类有活性,对全球感染性疾病治疗有显著贡献。
  • 左氧氟沙星和环丙沙星等氟喹诺酮因广谱抗菌活性、化学稳定性和高生物利用度仍是重要有效治疗选择。
  • 氟喹诺酮副作用引发美国、欧洲和英国发布警告。
  • 许多国家氟喹诺酮耐药菌流行率逐年稳步上升,对公共健康构成严重威胁。

临床怎么用

  • 临床应继续合理使用氟喹诺酮类,同时关注副作用和耐药监测。
  • 新型非喹诺酮拓扑异构酶抑制剂可能成为未来应对耐药的选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Bacterial topoisomerases are enzymes critical for maintaining genomic DNA integrity and ensuring bacterial cell survival, making them ideal targets for antibacterial agents. Bacterial topoisomerase inhibitors, such as quinolones and fluoroquinolones, target two enzymes, DNA gyrase and topoisomerase IV, and inhibit the control of DNA supercoiling/decatenation, leading to impaired DNA replication and bacterial cell death. Since their initial discovery, many quinolones and fluoroquinolones have been developed with activity against a wide range of bacterial species, contributing significantly to the treatment of various infectious diseases worldwide. Fluoroquinolones such as levofloxacin and ciprofloxacin remain important and effective therapeutic options today due to their broad-spectrum antibacterial activity, chemical stability and high bioavailability. However, side effects of fluoroquinolones have become a concern, leading to warnings being issued in the United States, Europe and the United Kingdom. Furthermore, in many countries, the prevalence of fluoroquinolone-resistant bacteria has been steadily increasing each year, which poses a serious threat to public health. The clinical development of new non-quinolone bacterial topoisomerase inhibitors (for example, zoliflodacin, gepotidacin and fobrepodacin) offers a promising solution to these issues and has the potential to play a crucial role in combating the growing problem of antimicrobial resistance. This review article will discuss the evolution of quinolone and fluoroquinolone antibacterial agents as key topoisomerase inhibitors, examine their current clinical applications and challenges to future development, and explore the potential of new topoisomerase inhibitors.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Fukuda D, Powell D, Mulgirigama A, et al. Bacterial DNA topoisomerase IV and DNA gyrase inhibitors: history of the quinolones, their clinical usage and potential alternatives for the future. J Antimicrob Chemother. 2026. PMID: 41710965. doi:10.1093/jac/dkag054

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。